High accuracy model for HBsAg loss based on longitudinal trajectories of serum qHBsAg throughout long-term antiviral therapy

Rong Fan,Siru Zhao,Junqi Niu,Hong Ma,Qing Xie,Song Yang,Jianping Xie,Xiaoguang Dou,Jia Shang,Huiying Rao,Qi Xia,Yali Liu,Yongfeng Yang,Hongbo Gao,Aimin Sun,Xieer Liang,Xueru Yin,Yongfang Jiang,Yanyan Yu,Jian Sun,Nikolai V Naoumov,Jinlin Hou,Chronic Hepatitis B Study Consortium,Mingxiang Zhang,Yuming Wang,Hong Tang,Huafa Yin,Zhengang Zhang,Qiang Li,Shumei Lin,Wu Li,Hong Ren,Maorong Wang,Yimin Mao,Huazhong Chen,Jianqi Lian,Feng Lin,Liaoyun Zhang,Chengzhong Li,Jinhua Hu,Jiefei Wang,Huimin Liu,Desheng Xie,Hong Wang,Chengwei Chen,Hao Ying,Tao Han,Mingliang Cheng,Jianhe Gan,Donghui Zhou,Yuxian Huang,Gongchen Wang,Feijian Ao,Zujiang Yu,Yuqiang Fu,Qin Ning

DOI: https://doi.org/10.1136/gutjnl-2024-332182

IF: 24.5

2024-06-27

Gut

Abstract:Objective: Hepatitis B surface antigen (HBsAg) loss is the optimal outcome for patients with chronic hepatitis B (CHB) but this rarely occurs with currently approved therapies. We aimed to develop and validate a prognostic model for HBsAg loss on treatment using longitudinal data from a large, prospectively followed, nationwide cohort. Design: CHB patients receiving nucleos(t)ide analogues as antiviral treatment were enrolled from 50 centres in China. Quantitative HBsAg (qHBsAg) testing was prospectively performed biannually per protocol. Longitudinal discriminant analysis algorithm was used to estimate the incidence of HBsAg loss, by integrating clinical data of each patient collected during follow-up. Results: In total, 6792 CHB patients who had initiated antiviral treatment 41.3 (IQR 7.6-107.6) months before enrolment and had median qHBsAg 2.9 (IQR 2.3-3.3) log10IU/mL at entry were analysed. With a median follow-up of 65.6 (IQR 51.5-84.7) months, the 5-year cumulative incidence of HBsAg loss was 2.4%. A prediction model integrating all qHBsAg values of each patient during follow-up, designated GOLDEN model, was developed and validated. The AUCs of GOLDEN model were 0.981 (95% CI 0.974 to 0.987) and 0.979 (95% CI 0.974 to 0.983) in the training and external validation sets, respectively, and were significantly better than those of a single qHBsAg measurement. GOLDEN model identified 8.5%-10.4% of patients with a high probability of HBsAg loss (5-year cumulative incidence: 17.0%-29.1%) and was able to exclude 89.6%-91.5% of patients whose incidence of HBsAg loss is 0. Moreover, the GOLDEN model consistently showed excellent performance among various subgroups. Conclusion: The novel GOLDEN model, based on longitudinal qHBsAg data, accurately predicts HBsAg clearance, provides reliable estimates of functional hepatitis B virus (HBV) cure and may have the potential to stratify different subsets of patients for novel anti-HBV therapies.